Navigation Links
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Date:4/10/2008

atients unable to exercise adequately. The most common side effects include flushing, chest discomfort and dyspnea. Less frequent side effects reported in patients administered Adenoscan include second and third degree AV block, fatal cardiac arrest, ventricular tachycardia and nonfatal myocardial infarction. For full prescribing information, please visit http://www.adenoscan.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

CV Therapeutics Conference Call

Company management will webcast a conference call on Friday, April 11, 2008 at 8:30 a.m. EDT, 5:30 a.m. PDT, on the company's website. To access the live webcast and corresponding slides, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, April 18, 2008. Domestic callers can access the replay by dialing (800) 642-1
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
5. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
9. Mercury Therapeutics Patents Filed
10. Cell Therapeutics, Inc. Announces Filing of Form 10-K
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 Press attending ... ways to take advantage of the people and events ... schedule below are available throughout the day. Additionally, we ... with POET and DSM representatives as well as representatives ... requests is appreciated. , Please remember to RSVP ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International Corporation ... its wholly-owned subsidiary Renuell Int,l, Inc. has signed an ... Space Administration ("NASA") at the Johnson Space Center in ... See photos: tapplic.com/houstonphotos/ ... very pleased to announce our latest, exclusive agreement with ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, Inc. ... U.S. Patent and Trademark Office (PTO) has issued a ... evaluated for weight loss. NB32 is a fixed-dose combination ... U.S. Patent No. 8,815,889 claims methods for treating ... The patent expires in 2024. If NB32 is approved ...
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... positive results from its final preclinical toxicology study ... (FDA) guidance, this bridging study was required to ... designed to prevent the devastating effects of ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... LELYSTAD, The Netherlands, December 2 Pepscan Holding ... the generation of immune therapeutics today announced that it,has appointed ... Dr. Mol will be responsible for ... direction of the company. He brings to,Pepscan more than 20 ...
... , RESTON, ... the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor ... China, today announced that the Company will be featured,in the ... magazine with a,readership of over 250,000 executives in the food ...
... ... covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s ... ... from Photometrics ®, a designer and manufacturer of high-performance CCD and EMCCD ...
Cached Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
(Date:9/2/2014)... published in the September issue of The ... novel strategy to diagnose the leading cause of ... damage has occurred. This advance involves quantifying the ... endothelium of retinal vessels. Using new probes developed ... early molecular development of diabetic retinopathy. , "My ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
Breaking Biology News(10 mins):Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... at Dana-Farber Cancer Institute and the Broad Institute of MIT ... genes that may serve as an Achilles, heel for many ... issue of the journal Cell , the researchers identified ... been identified as potential targets for cancer therapy. Unlike most ...
... A University of Toronto (U of T) team led by Engineering ... garnered third place and $40,000 (USD) for their design of a ... to the Bill & Melinda Gates Foundation,s Reinvent the Toilet Challenge, ... and affordable for people in the developing world that doesn,t have ...
... Uzuntarla from Bulent Ecevit University, Turkey, and his colleagues ... which is present in the nervous system. The article ... work has implications for explaining how noise, modulated by ... of neurons to external stimuli as part of the ...
Cached Biology News:'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3University of Toronto wins third place at the Gates Foundation's Reinvent the Toilet Challenge 2
TNM-FH Insect Medium 1 liter...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
... PureLink PCR Purification Kits provide rapid ... enzymes, short-failed PCR products, and salts from ... bind/wash/elute procedure:, provides two Binding Buffer ... bp* , can be performed in either ...
Biology Products: